04/30/2024 | Press release | Distributed by Public on 04/30/2024 09:57
April 30, 2024
BRUSSELS-Covington provides competition/anti-trust, intellectual property and regulatory advice to INTREPID Alliance, a not-for-profit consortium of innovative biopharmaceutical companies dedicated to accelerating antiviral treatments to help protect the world ahead of future pandemics.
Building on its commitment to identify strengths and gaps in the R&D pipeline for antivirals, the INTREPID Alliance today published the second edition of its Antiviral Clinical Development Landscape. This ongoing scientific review and triage of a global R&D database of clinical antivirals reveals concerning gaps in the development of promising clinical compounds targeting 12 viral families of greatest pandemic potential.
The Covington team is led by Winsome Cheung and Sibel Yilmaz and includes Sarah Cowlishaw, Inga Pietsch, Bethan Lukey, and Oliver Hodgkiss.